Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
ABSTRACT The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV). The ZSVG-02-O induces neutralizing antibodies that effectively cross-react with Omicron subvariants following an order of BA.1>BA.2>BA.4/5. In naïve animals, ZSVG-02 or ZSVG-02-O induce humoral responses skewed to the vaccine’s targeting strains, but cellular immune responses cross-react to all variants of concern (VOCs) tested. Following heterologous prime-boost regimes, animals present comparable neutralizing antibody levels and superior protection across all VOCs. Single-boost only generated ancestral and omicron dual-responsive antibodies, probably by “recall” and “reshape” the prime immunity. New Omicron-specific antibody populations, however, appeared only following the second boost with ZSVG-02-O. Overall, our results support a heterologous boost with ZSVG-02-O, providing the best protection against current VOCs in inactivated virus vaccine– primed populations..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Changrui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.09.06.506714 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037222317 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037222317 | ||
| 003 | DE-627 | ||
| 005 | 20240425104420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.09.06.506714 |2 doi | |
| 035 | |a (DE-627)XBI037222317 | ||
| 035 | |a (biorXiv)10.1101/2022.09.06.506714 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Changrui |e verfasserin |0 (orcid)0000-0002-2171-9888 |4 aut | |
| 245 | 1 | 0 | |a Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV). The ZSVG-02-O induces neutralizing antibodies that effectively cross-react with Omicron subvariants following an order of BA.1>BA.2>BA.4/5. In naïve animals, ZSVG-02 or ZSVG-02-O induce humoral responses skewed to the vaccine’s targeting strains, but cellular immune responses cross-react to all variants of concern (VOCs) tested. Following heterologous prime-boost regimes, animals present comparable neutralizing antibody levels and superior protection across all VOCs. Single-boost only generated ancestral and omicron dual-responsive antibodies, probably by “recall” and “reshape” the prime immunity. New Omicron-specific antibody populations, however, appeared only following the second boost with ZSVG-02-O. Overall, our results support a heterologous boost with ZSVG-02-O, providing the best protection against current VOCs in inactivated virus vaccine– primed populations. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Zhang, Yuntao |e verfasserin |0 (orcid)0000-0002-0557-5693 |4 aut | |
| 700 | 1 | |a Liu, Xiaohu |e verfasserin |0 (orcid)0000-0002-8894-4633 |4 aut | |
| 700 | 1 | |a Hou, Fujun |e verfasserin |0 (orcid)0000-0002-8617-9472 |4 aut | |
| 700 | 1 | |a Cai, Rujie |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Zhibin |e verfasserin |0 (orcid)0000-0002-9950-1272 |4 aut | |
| 700 | 1 | |a Liu, Fei |e verfasserin |0 (orcid)0000-0001-8688-1010 |4 aut | |
| 700 | 1 | |a Yang, Guohuan |e verfasserin |0 (orcid)0000-0001-7903-8017 |4 aut | |
| 700 | 1 | |a Ding, Jun |e verfasserin |0 (orcid)0000-0003-3686-1710 |4 aut | |
| 700 | 1 | |a Xu, Jiang |e verfasserin |0 (orcid)0000-0002-6369-0198 |4 aut | |
| 700 | 1 | |a Hua, Xianwu |e verfasserin |0 (orcid)0000-0001-6178-5639 |4 aut | |
| 700 | 1 | |a Pan, Xinping |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lianxiao |e verfasserin |0 (orcid)0000-0001-5914-7064 |4 aut | |
| 700 | 1 | |a Lin, Kang |e verfasserin |0 (orcid)0000-0002-0464-4693 |4 aut | |
| 700 | 1 | |a Wang, Zejun |e verfasserin |0 (orcid)0000-0003-0313-5819 |4 aut | |
| 700 | 1 | |a Li, Xinguo |e verfasserin |0 (orcid)0000-0002-9619-9389 |4 aut | |
| 700 | 1 | |a Lu, Jia |e verfasserin |0 (orcid)0000-0001-5084-818X |4 aut | |
| 700 | 1 | |a Zhang, Qiu |e verfasserin |0 (orcid)0000-0001-5955-9966 |4 aut | |
| 700 | 1 | |a Li, Yuwei |e verfasserin |0 (orcid)0000-0002-5488-242X |4 aut | |
| 700 | 1 | |a Hu, Chunxia |e verfasserin |0 (orcid)0000-0001-8381-4664 |4 aut | |
| 700 | 1 | |a Fan, Huifeng |e verfasserin |0 (orcid)0000-0002-1127-4256 |4 aut | |
| 700 | 1 | |a Liu, Xiaoke |e verfasserin |0 (orcid)0000-0002-3855-8099 |4 aut | |
| 700 | 1 | |a Wang, Hui |e verfasserin |0 (orcid)0000-0003-0171-7591 |4 aut | |
| 700 | 1 | |a Jia, Rui |e verfasserin |0 (orcid)0000-0001-8738-0066 |4 aut | |
| 700 | 1 | |a Xu, Fangjingwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuewei |e verfasserin |0 (orcid)0000-0002-6887-1983 |4 aut | |
| 700 | 1 | |a Huang, Hongwei |e verfasserin |0 (orcid)0000-0001-9285-6815 |4 aut | |
| 700 | 1 | |a Zhao, Ronghua |e verfasserin |0 (orcid)0000-0002-2208-1505 |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |0 (orcid)0000-0003-1445-5367 |4 aut | |
| 700 | 1 | |a Cheng, Hang |e verfasserin |0 (orcid)0000-0001-6156-8220 |4 aut | |
| 700 | 1 | |a Jia, William |e verfasserin |0 (orcid)0000-0002-2755-6821 |4 aut | |
| 700 | 1 | |a Yang, Xiaoming |e verfasserin |0 (orcid)0000-0001-9711-6904 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.antiviral.2023.105556 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.09.06.506714 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||